Valeant vaulted over very ‘lowball’ earnings estimates and that is why the stock is popping today, says TheStreet’s Jim Cramer. The beleaguered pharmaceutical company reported lower-than-expected results for the 2016 second quarter, but reiterated upbeat guidance for the year. Before Tuesday’s market open, Valeant maintained its projection for full-year revenue in the range of $9.9 billion to $10.1 billion. For the 2016 second quarter, the Quebec-based company reported adjusted earnings of $1.40 a share, below analysts’ estimates of $1.48 a share.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
